7 April 2014
Starpharma expands its Drug Delivery Program with AstraZeneca
Starpharma today announced the signing of a second, expanded agreement with AstraZeneca in the field of cancer medicine using Starpharma’s proprietary DEP™ dendrimer drug delivery technology.
The agreement follows on from an evaluation by AstraZeneca which began in September 2012 of Starpharma’s delivery technology. The new agreement will see the application of Starpharma’s technology to a cancer drug, from AstraZeneca’s pipeline.Read more